Clinical outcomes in ocular pythiosis patients treated with a combination therapy protocol in Thailand: A prospective study.
Adult
Antibodies, Fungal
/ blood
Antifungal Agents
/ administration & dosage
Antigens, Fungal
/ administration & dosage
Combined Modality Therapy
/ methods
Diagnostic Tests, Routine
/ methods
Eye Infections, Fungal
/ diagnosis
Female
Humans
Immunologic Factors
/ administration & dosage
Male
Microbial Sensitivity Tests
Middle Aged
Prospective Studies
Proteoglycans
Pythiosis
/ diagnosis
Pythium
/ drug effects
Thailand
Treatment Outcome
Young Adult
beta-Glucans
/ blood
P.insidiosum; fungal keratitis
beta-d-glucan
fungal endophthalmitis
fungal markers
pythiosis
Journal
Medical mycology
ISSN: 1460-2709
Titre abrégé: Med Mycol
Pays: England
ID NLM: 9815835
Informations de publication
Date de publication:
01 Nov 2019
01 Nov 2019
Historique:
received:
21
11
2018
revised:
17
12
2018
accepted:
04
02
2019
pubmed:
26
2
2019
medline:
17
1
2020
entrez:
27
2
2019
Statut:
ppublish
Résumé
Ocular pythiosis is the second most common form of human pythiosis, and the rates of evisceration/enucleation in Thailand are 55-79%. This prospective study was conducted to evaluate treatment outcomes of the combination therapy protocol and the potential use of serum (1→3)-β-glucan (BG) and Pythium insidiosum-specific antibody (Pi-Ab) as an aid to diagnosis and monitoring of ocular pythiosis. Thirty patients were enrolled in the study and 14 (non-globe salvage) required evisceration/enucleation. The globe salvage group was significantly younger, and first ocular surgeries were performed significantly sooner than in the non-globe salvage group. Serum BG and Pi-Ab levels were similar among the 2 groups over time. In vitro susceptibility testing of antifungal agents revealed relatively high minimum inhibitory concentrations and lack of synergistic effect. Serum BG and Pi-Ab would not be useful in diagnosis and monitoring of ocular pythiosis. Until effective antimicrobial agents are discovered, ocular surgeries are still the mainstay therapy in Thailand.
Identifiants
pubmed: 30805615
pii: 5365183
doi: 10.1093/mmy/myz013
doi:
Substances chimiques
Antibodies, Fungal
0
Antifungal Agents
0
Antigens, Fungal
0
Immunologic Factors
0
Proteoglycans
0
beta-Glucans
0
polysaccharide-K
3X48A86C8K
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
923-928Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.